{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifal3z565rvzhalszgel5j3hpnw72mxgajg4flqikns3p6oe77ttq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mgy6b7s5mn22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihkawzmnslrhtds3gzdjcqkntnetbbqdizwfu2dxnnj2dp4ngolbq"
    },
    "mimeType": "image/jpeg",
    "size": 107136
  },
  "path": "/news/2026-03-glp-receptor-agonists-linked-mortality.html",
  "publishedAt": "2026-03-13T20:20:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open.",
  "title": "GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM"
}